Quick Answer
Theriva Biologics, Inc. reported Total Revenue of $0.00 for fiscal year 2011.
Theriva Biologics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | — | — | -$18.35M +6.8% |
-$19.68M -38.0% |
-$14.27M -42.1% |
-$10.04M +34.4% |
| Diluted EPS | -$2.08 +89.1% |
-$19.03 +33.2% |
-$28.48 -2074.0% |
-$1.31 +31.1% |
-$1.90 -187.9% |
-$0.66 |
| Total Assets | $38.24M +8.2% |
$35.35M -36.0% |
$55.22M -31.5% |
$80.64M +14.6% |
$70.36M +736.7% |
$8.41M -51.2% |
| Cash and Equivalents | $13.06M +12.5% |
$11.61M -49.9% |
$23.18M -55.7% |
$52.27M -22.4% |
$67.33M +981.2% |
$6.23M -76.0% |
| Stockholders Equity | $15.38M -19.3% |
$19.07M -48.4% |
$36.96M -45.7% |
$68.03M +4.0% |
$65.41M +1472.1% |
-$4.77M -196.7% |
| R&D Expense | $8.60M -28.5% |
$12.03M -15.9% |
$14.31M +22.1% |
$11.72M +50.3% |
$7.80M +52.0% |
$5.13M -53.7% |
| Operating Income | -$24.05M +8.7% |
-$26.35M -22.9% |
-$21.43M +0.7% |
-$21.58M -51.2% |
-$14.27M -40.5% |
-$10.16M +35.1% |
| Shares Outstanding | 35.69M +3450.2% |
1.01M +46.5% |
686,219 -95.7% |
15.84M +20.0% |
13.20M -54.9% |
29.25M +74.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2011 | $293.4K | +1.2% | -17.5% |
| Net Income | September 30, 2023 | -$3.30M | +26.4% | +26.4% |
| Diluted EPS | September 30, 2025 | -$0.45 | +93.4% | +76.7% |
| Total Assets | September 30, 2025 | $30.84M | -23.1% | -13.9% |
| Cash and Equivalents | September 30, 2025 | $7.53M | -54.1% | -37.9% |
| Stockholders Equity | September 30, 2025 | $6.74M | -72.6% | -36.6% |
| R&D Expense | September 30, 2025 | $2.55M | -6.7% | +30.6% |
| Operating Income | September 30, 2025 | -$4.44M | +43.7% | +66.2% |
| Shares Outstanding | September 30, 2025 | 10.30M | +293.7% | +13.7% |
- Theriva Biologics, Inc. reported Total Revenue of $0.00 for fiscal year 2011.
- Theriva Biologics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Net Income of -$18.35 million for fiscal year 2023.
- Theriva Biologics, Inc. showed an increase of +6.8% in Net Income compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Diluted EPS of $2.08 per share (loss) for fiscal year 2025.
- Theriva Biologics, Inc. showed an increase of +89.1% in Diluted EPS compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Total Assets of $38.24 million for fiscal year 2025.
- Theriva Biologics, Inc. showed an increase of +8.2% in Total Assets compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Cash and Equivalents of $13.06 million for fiscal year 2025.
- Theriva Biologics, Inc. showed an increase of +12.5% in Cash and Equivalents compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Stockholders Equity of $15.38 million for fiscal year 2025.
- Theriva Biologics, Inc. showed a decrease of -19.3% in Stockholders Equity compared to the prior fiscal year.
- Theriva Biologics, Inc. reported R&D Expense of $8.60 million for fiscal year 2025.
- Theriva Biologics, Inc. showed a decrease of -28.5% in R&D Expense compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Operating Income of -$24.05 million for fiscal year 2025.
- Theriva Biologics, Inc. showed an increase of +8.7% in Operating Income compared to the prior fiscal year.
- Theriva Biologics, Inc. reported Shares Outstanding of 35.69 million shares for fiscal year 2025.
- Theriva Biologics, Inc. showed an increase of +1182.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: